FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a a a P ' R b C a ab)

(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT

( )

( )-

( ) - (

Company **Group**) (**2021 First Quarterly Report**)

(**Reporting Period**)-

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* *for identification purposes only*

1. IMPORTANT NOTICE

- [illegible] (the "**Board**") [illegible] (the "**Supervisory Committee**") [illegible]

- [illegible]

- [illegible] ([illegible]) [illegible]

- [illegible]

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

	31 March 2021	31 December 2020	Ratio of change (%)
	Jan – Mar 2021	**Jan – Mar 2020**	**Period-on-period change (%)**
	Jan – Mar 2021	**Jan – Mar 2020**	**Period-on-period change (%)**
(%)			
( )			
( )			

Note 1:) (**PRC**)

Note 2: % % % ( ) ( ) ( ) ( ))

[illegible]

[illegible]

Items	Jan – Mar 2021
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

[illegible]

[illegible]

[illegible]					
[illegible]					
[illegible]				[illegible]	[illegible]
[illegible]				[illegible]	[illegible]
[illegible]					

3. SIGNIFICANT EVENTS

[illegible]

( ) [illegible]

[illegible]

Balance Sheet				
Item	**Balance at the end of the Reporting Period**	**Balance at the beginning of the year**	**Ratio of change**	**Reason**
[illegible]	[illegible]	[illegible]	[illegible] %	[illegible]
[illegible]	[illegible]	[illegible]	[illegible] %	[illegible]
[illegible]	[illegible]	[illegible]	[illegible] %	[illegible]
[illegible]	[illegible]	[illegible]	[illegible] %	[illegible]
[illegible]	[illegible]	[illegible]	[illegible] %	[illegible]

( ) [illegible]

[illegible]

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan – Mar 2021	Jan – Mar 2020		
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]

( )

(**Non-public Offering**)

(**CSRC**)(《中國證監會行政許可申請受理單》)

《中國證監會行政許可項目審查一次反饋意見通知書》

①

(**21 Fosun Pharma 01**)

② [illegible] %

③ [illegible] (**16 Fosun Pharma 01**)-

[illegible] (**2021 Restricted Share Incentive Scheme**) [illegible] %

(- [illegible])- [illegible] %

[illegible] %

[illegible] %

[illegible]

[illegible]

[illegible]

[illegible]

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible] **Wu Yifang**

[illegible]

* *for identification purposes only*

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Non-current assets:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Consolidated Balance Sheet *(Continued)*

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Non-current liabilities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Equity:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Legal Representative:	*Chief Financial Officer:*	*Director of the Accounting Department:*
Wu Yifang	**Guan Xiaohui**	**Yan Jia**

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Non-current assets:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Current liabilities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Balance Sheet of the Parent Company *(Continued)*

31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Equity:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Legal Representative: **Wu Yifang**

Chief Financial Officer: **Guan Xiaohui**

Director of the Accounting Department: **Yan Jia**

Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
(1) [illegible]		
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])		
(2) [illegible]		
[illegible] (Expressed in [illegible])	[illegible]	[illegible]
[illegible] (Expressed in [illegible])	[illegible]	[illegible]

Consolidated Income Statement *(Continued)*

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
(1) [illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
(11) [illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
(1) [illegible]	[illegible]	[illegible]
(11) [illegible]	[illegible]	[illegible]

Legal Representative: **Wu Yifang**

Chief Financial Officer: **Guan Xiaohui**

Director of the Accounting Department: **Yan Jia**

Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible]

Items	Jan – Mar 2021	Jan – Mar 2020
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Income Statement of the Parent Company *(Continued)*

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
[illegible]	[illegible]	[illegible]
[illegible]		
(I) [illegible]	[illegible]	[illegible]
(II) [illegible]	[illegible]	[illegible]

Legal Representative:	*Chief Financial Officer:*	*Director of the Accounting Department:*
Wu Yifang	**Guan Xiaohui**	**Yan Jia**

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
II. Cash flow generated from investing activities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

Consolidated Statement of Cash Flow *(Continued)*

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
III. Cash flow generated from financing activities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
IV. Effects of exchange rate fluctuations on cash and cash equivalents	[illegible]	[illegible]
V. Net increase of cash and cash equivalents	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
VI. Closing balance of cash and cash equivalents	[illegible]	[illegible]

Legal Representative:	*Chief Financial Officer:*	*Director of the Accounting Department:*
Wu Yifang	**Guan Xiaohui**	**Yan Jia**

Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
II. Cash flow generated from investing activities:		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
